Beta
ManageSearchChatDiscover
301123

THE EFFECT OF MELATONIN, METFORMIN AND URSODEOXYCHOLIC ACID ON NON-ALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED, DOUBLE-BLINDED CONTROLLED TRIAL

Article

Last updated: 25 Dec 2024

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Objective: This study was to investigate and compare the effect of melatonin, metformin, and ursodeoxycholic acid (UDCA) on non-alcoholic fatty liver disease(NAFLD). Methods: In this randomized double-blinded clinical trial, 120 patients with NAFLD who had been referred to Gastrointestinal and Liver Diseases Research Center, Rasht, Iran, between September 2015 and January 2016. Patients were randomly assigned to 4 groups. Each group received melatonin, metformin, UDCA, or placebo in addition to a weight loss diet for 3 months. Results: A significant reduction was observed in levels of steatosis, alanine aminotransferase, alkaline phosphatase, body weight, BMI, waist circumstance and triacylglycerol among participants in groups with metformin or melatonin administration. In addition a significant decrease in fasting plasma glucose, and total cholesterol concentration was detected following metformin and UDCA administration, respectively. Conclusions: The present study suggests that the addition of metformin or melatonin to a low-caloric diet may be effective in the treatment of patients with NAFLD.

DOI

10.21608/bfsa.2023.301123

Keywords

Melatonin, Metformin, ursodeoxycholic acid, Non-alcoholic fatty liver disease

Authors

First Name

Kourosh

Last Name

Mojtahedi

MiddleName

-

Affiliation

Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran

Email

k.moj2013@yahoo.com

City

-

Orcid

0000-0002-6755-3027

First Name

Farahnaz

Last Name

Joukar

MiddleName

-

Affiliation

Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran

Email

farajov@gmail.com

City

-

Orcid

0000-0001-8432-8879

First Name

Seyyed

Last Name

Fahim

MiddleName

Hossein Seyyed Nezhad

Affiliation

Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran

Email

-

City

-

Orcid

-

First Name

Sara

Last Name

Yeganeh

MiddleName

-

Affiliation

Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran

Email

yeganeh_sara6@yahoo.com

City

-

Orcid

0000-0002-6298-7109

First Name

Mehrnaz

Last Name

Asgharnezhad

MiddleName

-

Affiliation

Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran

Email

asgharnezhad98@yahoo.com

City

-

Orcid

-

First Name

Afshin

Last Name

Shafaghi

MiddleName

-

Affiliation

Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran

Email

-

City

-

Orcid

-

First Name

Saba

Last Name

Asl

MiddleName

Fakhrieh

Affiliation

Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran

Email

-

City

-

Orcid

-

First Name

Fariborz

Last Name

Mansour-Ghanaei

MiddleName

-

Affiliation

Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran

Email

fmansourghanaei@gmail.com

City

-

Orcid

0000-0002-6264-0025

Volume

46

Article Issue

1

Related Issue

41495

Issue Date

2023-06-01

Receive Date

2022-11-27

Publish Date

2023-06-01

Page Start

347

Page End

360

Print ISSN

1110-0052

Online ISSN

3009-7703

Article File

BFSA_Volume 46_Issue 1_Pages 347-360.pdf

PDF . 962.4kB

Link

https://bpsa.journals.ekb.eg/article_301123.html

Detail API

https://bpsa.journals.ekb.eg/service?article_code=301123

Order

301,123

Type

Original Article

Type Code

1,096

Publication Type

Journal

Publication Title

Bulletin of Pharmaceutical Sciences Assiut University

Publication Link

https://bpsa.journals.ekb.eg/

MainTitle

THE EFFECT OF MELATONIN, METFORMIN AND URSODEOXYCHOLIC ACID ON NON-ALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED, DOUBLE-BLINDED CONTROLLED TRIAL

Details

Type

Article

Created At

25 Dec 2024